INFORMATION
Ustekinumab is a fully humanised IgG1 therapeutic monoclonal antibody used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. It targets cytokines IL-12 and IL-23, which are involved in immune-mediated inflammatory disorders.
The IDKmonitor Ustekinumab TOTAL Anti-drug Antibody ELISA measures free and bound antibodies against ustekinumab (e.g. STELARA®). This drug-tolerant assay enables the reliable determination of anti-drug antibodies even in the presence of ustekinumab. This means it is ideal for therapy monitoring when a measurable ustekinumab concentration is expected, for example, shortly after the last infusion. In combination with the drug level determination, the IDKmonitor Ustekinumab TOTAL Anti-drug Antibody ELISA supports the monitoring and optimisation of therapy.
KEY ADVANTAGES
-
Supports the investigation of primary non-response and loss of response to ustekinumab
-
Highly sensitive assay that detects free anti-ustekinumab antibodies (those unbound to ustekinumab)
-
May help to predict long term outcome of disease
- Identifies patients with low-titre anti-ustekinumab antibodies
-
Applicable to both gastroenterology and rheumatology
-
Automatable on ELISA automates (e.g. Dynex D2)
